Understanding Actemra®
Actemra® (tocilizumab) is a monoclonal antibody that helps regulate the immune system by blocking interleukin-6 (IL-6) receptors, a key driver of inflammation in autoimmune diseases. It is used to treat various types of arthritis and immune-related conditions when other treatments, such as TNF inhibitors, have not been effective.
How Actemra® Works:
- Targets and blocks IL-6 receptors, reducing the effects of IL-6, a protein that causes inflammation.
- Helps protect healthy cells from immune system attacks, minimizing inflammation and joint damage.
- Reduces joint pain, swelling, and stiffness in arthritis patients.
- Lowers the risk of vascular complications in Giant Cell Arteritis (GCA).
FDA Approval:
- 2010 – Approved for Rheumatoid Arthritis and other autoimmune conditions.
For more information, please visit the Actemra® patient website. Speak with your healthcare provider to determine if Actemra® is the right treatment option for you.